D. Cui

发表

Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme

I. Mcintosh, J. Wagner, K. Lasseter, 2007, Drug Metabolism and Disposition.

Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.

Steven V. Fox, John D. Schreier, J. Renger, 2014, Bioorganic & medicinal chemistry letters.

Pharmacokinetic Drug Interactions Involving 17α-Ethinylestradiol

A. D. Rodrigues, P. Balimane, Hongjiang Zhang, 2007 .

Confirmation That Cytochrome P450 2C8 (CYP2C8) Plays a Minor Role in (S)-(+)- and (R)-(-)-Ibuprofen Hydroxylation in Vitro

A. D. Rodrigues, Hongjiang Zhang, B. Wen, 2008, Drug Metabolism and Disposition.

In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans

T. Prueksaritanont, K. Yee, J. McCrea, 2016, Xenobiotica; the fate of foreign compounds in biological systems.

Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.

Steven V. Fox, I. Raheem, J. Renger, 2015, Bioorganic & medicinal chemistry letters.

Discovery of [(2R,5R)‐5‐{[(5‐Fluoropyridin‐2‐yl)oxy]methyl}‐2‐methylpiperidin‐1‐yl][5‐methyl‐2‐(pyrimidin‐2‐yl)phenyl]methanone (MK‐6096): A Dual Orexin Receptor Antagonist with Potent Sleep‐Promoting Properties

Steven V. Fox, John D. Schreier, S. Doran, 2012, ChemMedChem.

Identification and human exposure prediction of two aldehyde oxidase-mediated metabolites of a methylquinoline-containing drug candidate

E. Hellriegel, Austin C. Li, D. Cui, 2019, Xenobiotica; the fate of foreign compounds in biological systems.

Heterotropic modulation of sulfotransferase 2A1 activity by celecoxib: product ratio switching of ethynylestradiol sulfation.

B. Carr, E. Carlini, Catherine L. Booth-Genthe, 2004, Drug metabolism and disposition: the biological fate of chemicals.

IN VITRO AND IN VIVO METABOLISM OF A POTENT AND SELECTIVE INTEGRIN (cid:1) v (cid:2) 3 ANTAGONIST IN RATS, DOGS, AND MONKEYS

J. Yergey, R. Subramanian, M. Braun, 2004 .

Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

A. D. Rodrigues, P. Balimane, Hongjiang Zhang, 2007, Clinical pharmacokinetics.

METABOLISM AND DISPOSITION OF A POTENT AND SELECTIVE GABA-Aα2/3 RECEPTOR AGONIST IN HEALTHY MALE VOLUNTEERS

A. D. Rodrigues, R. Subramanian, K. Lasseter, 2006, Drug Metabolism and Disposition.

Preclinical pharmacokinetics of MK-0974, an orally active calcitonin-gene related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences.

B. Wong, T. Prueksaritanont, S. Roller, 2009, Xenobiotica; the fate of foreign compounds in biological systems.

The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold

Steven V. Fox, J. Uslaner, J. Renger, 2013, BMC Neuroscience.

Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.

John D. Schreier, S. Doran, G. McGaughey, 2010, Journal of medicinal chemistry.

Discovery of 5′′‐Chloro‐N‐[(5,6‐dimethoxypyridin‐2‐yl)methyl]‐2,2′:5′,3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia

Steven V. Fox, John D. Schreier, J. Renger, 2014, ChemMedChem.

Contribution of Metabolites to P450 Inhibition–Based Drug–Drug Interactions: Scholarship from the Drug Metabolism Leadership Group of the Innovation and Quality Consortium Metabolite Group

W. Humphreys, R. Walsky, C. Prakash, 2015, Drug Metabolism and Disposition.

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

W. Humphreys, F. Lee, A. Allentoff, 2008, Drug Metabolism and Disposition.

Identification of in vitro metabolites of indinavir by “intelligent automated LC-MS/MS” (INTAMS) utilizing triple quadrupole tandem mass spectrometry

M. Davis, D. Cui, Xiao Yu, 1999, Journal of the American Society for Mass Spectrometry.

Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol.

A. D. Rodrigues, Donghui Cui, B. Ma, 2004, Drug metabolism and disposition: the biological fate of chemicals.

IN VITRO AND IN VIVO METABOLISM OF A POTENT AND SELECTIVE INTEGRIN v 3 ANTAGONIST IN RATS , DOGS , AND MONKEYS

J. Yergey, R. Subramanian, M. Braun, 2004 .

In vitro drug–drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes

Nancy F. Chen, D. Welty, Qing Wang, 2018, Xenobiotica; the fate of foreign compounds in biological systems.

Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective

Donghui Cui, Thomayant Prueksaritanont, X. Chu, 2013, The AAPS Journal.

Identification of the Human Enzymes Involved in the Oxidative Metabolism of Dasatinib: An Effective Approach for Determining Metabolite Formation Kinetics

W. Humphreys, Donglu Zhang, R. Iyer, 2008, Drug Metabolism and Disposition.

Metabolism of rofecoxib in vitro using human liver subcellular fractions.

T. Baillie, P. Lu, B. Arison, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Biotransformation of [14C]Dasatinib: In Vitro Studies in Rat, Monkey, and Human and Disposition after Administration to Rats and Monkeys

W. Humphreys, V. Arora, K. He, 2008, Drug Metabolism and Disposition.

Biotransformation of [14C]Dasatinib: In Vitro Studies in Rat, Monkey, and Human and Disposition after Administration to Rats and Monkeys

W. Humphreys, V. Arora, K. He, 2008, Drug Metabolism and Disposition.

Contribution of Metabolites to P 450 Inhibition – Based Drug – Drug Interactions : Scholarship from the Drug Metabolism Leadership Group of the Innovation and Quality Consortium Metabolite Group s

W. Humphreys, R. Walsky, C. Prakash, 2015 .

Promotion of Sleep by Suvorexant—A Novel Dual Orexin Receptor Antagonist

Steven V. Fox, S. Doran, J. Renger, 2011, Journal of neurogenetics.

Pharmacological characterization of MK-6096 – A dual orexin receptor antagonist for insomnia

Steven V. Fox, John D. Schreier, S. Doran, 2012, Neuropharmacology.

Determination of the site of glucuronidation in an N-(3,5-dichlorophenyl)succinimide metabolite by electrospray ionization tandem mass spectrometry following derivatization to picolinyl esters.

D. Cui, P. J. Harvison, 2000, Rapid communications in mass spectrometry : RCM.

Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers.

A. D. Rodrigues, C. Matthews, K. Lasseter, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Cytochrome P450 3A-Dependent Metabolism of a Potent and Selective γ-Aminobutyric AcidAα2/3 Receptor Agonist in Vitro: Involvement of Cytochrome P450 3A5 Displaying Biphasic Kinetics

A. D. Rodrigues, B. Ma, D. Cui, 2007, Drug Metabolism and Disposition.

Metabolism, Distribution and Excretion of a Selective N-Methyl-d-Aspartate Receptor Antagonist, Traxoprodil, in Rats and Dogs

C. Prakash, M. Potchoiba, D. Cui, 2007, Drug Metabolism and Disposition.

“DMD #16105” 1 METABOLISM, DISTRIBUTION AND EXCRETION OF A SELECTIVE NMDA RECEPTOR ANTAGONIST, TRAXOPRODIL, IN RATS AND DOGS

C. Prakash, D. Cui, T. Butler, 2007 .

Metabolism of the nephrotoxicant N-(3,5-dichlorophenyl)succinimide in rats: evidence for bioactivation through alcohol-O-glucuronidation and O-sulfation.

G. Rankin, D. Cui, P. J. Harvison, 2005, Chemical research in toxicology.

TRANSAMINATION IN THE METABOLISM OF THE NEPHROTOXICANT N-(3,5-DICHLOROPHENYL)SUCCINIMIDE IN RATS

G. Rankin, D. Cui, P. J. Harvison, 2005, Drug Metabolism and Disposition.

Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs).

J. Renger, P. Coleman, S. Garson, 2013, Bioorganic & medicinal chemistry letters.

Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective

X. Chu, J. Hochman, T. Prueksaritanont, 2013, The AAPS Journal.

In Vitro Assessment of Drug-Drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters

X. Chu, R. Evers, T. Prueksaritanont, 2013, Drug Metabolism and Disposition.

Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.

C. Prakash, D. Cui, D. Cui, 1997, Drug metabolism and disposition: the biological fate of chemicals.

The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects.

T. Baillie, M. Davis, C. Matthews, 2002, Drug metabolism and disposition: the biological fate of chemicals.

In vitro and in vivo metabolism of a potent and selective integrin alpha v beta 3 antagonist in rats, dogs, and monkeys.

J. Yergey, R. Subramanian, M. Braun, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Microsoft Word-826811-file00.docx

T. Prueksaritanont, G. Chan, Cuyue Tang, 2013 .

Confirmation That Cytochrome P450 2C8 (CYP2C8) Plays a Minor Role in (S)-(+)- and (R)-(-)-Ibuprofen Hydroxylation in Vitro

Hongjiang Zhang, B. Wen, Shu-Ying Chang, 2008, Drug Metabolism and Disposition.

Characterization of the novel benzisothiazole ring-cleaved products of the antipsychotic drug ziprasidone.

C. Prakash, D. Cui, A. Kamel, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Identification of the Human Enzymes Involved in the Oxidative Metabolism of Dasatinib: An Effective Approach for Determining Metabolite Formation Kinetics

Donglu Zhang, R. Iyer, Lifei Wang, 2008, Drug Metabolism and Disposition.